Press release
Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharma
Non-Alcoholic Steatohepatitis Pipeline Insight 2024
As per DelveInsight's assessment, globally, about 100+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Alcoholic Steatohepatitis (NASH) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
" [https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-Alcoholic Steatohepatitis Market.
The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis and the aggregate therapies developed by major pharma companies.
*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Alcoholic Steatohepatitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
[https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The report covers the emerging products under different phases of clinical development like -
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Route of Administration
Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intra-articular
*
Intraocular
*
Intrathecal
*
Intravenous
*
Ophthalmic
*
Oral
*
Parenteral
*
Subcutaneous
*
Topical
*
Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
*
Oligonucleotide
*
Peptide
*
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Non-Alcoholic Steatohepatitis Therapeutic Segment @ [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Non-Alcoholic Steatohepatitis (NASH) Therapeutics Assessment
There are approx. 130+ key companies developing therapies for Non-Alcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Non-Alcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market Include:
Akero Therapeutics, Albireo Pharma, Altimmune, Inc., Amgen, ARTham Therapeutics, Ascletis, AstraZeneca, Bird Rock Bio, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cirius Therapeutics, DURECT Corporation, Enanta Pharmaceuticals, Enzychem Lifesciences, Galecto Biotech, Gmax Biopharm, GSK plc., Guangdong Zhongsheng Pharmaceutical, Hepion Pharmaceuticals, Ildong Pharmaceutical, Ildong Pharmaceutical, InorbitTX, Ionis Pharmaceuticals, J2H Biotech, LG Chem Life sciences, Liminal BioSciences, Madrigal Pharmaceuticals, Melior Pharmaceuticals, Merck Sharp & Dohme LLC, NorthSea Therapeutics, Palobiofarma, Pharmaxis, Pliant Therapeutics, Rivus Pharmaceuticals, Sciwind Biosciences, SCOHIA PHARMA, TaiwanJ Pharmaceuticals, Thoth Science, Tiziana Life Sciences, TransThera Biosciences, Viking Therapeutics, and many others.
Non-Alcoholic Steatohepatitis Emerging and Marketed Drugs Covered in the Report Include:
*
Resmetirom: Madrigal Pharmaceuticals
*
MSDC-0602K: Cirius Therapeutics
*
ION224: Ionis Pharmaceuticals
*
HU 6: Rivus Pharmaceuticals
*
HTD 1801: HighTide Biopharma
*
EDP-305: Enanta Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Steatohepatitis Current Treatment Patterns
4. Non-Alcoholic Steatohepatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Steatohepatitis Late Stage Products (Phase-III)
7. Non-Alcoholic Steatohepatitis Mid-Stage Products (Phase-II)
8. Non-Alcoholic Steatohepatitis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Steatohepatitis Discontinued Products
13. Non-Alcoholic Steatohepatitis Product Profiles
14. Key Companies in the Non-Alcoholic Steatohepatitis Market
15. Key Products in the Non-Alcoholic Steatohepatitis Therapeutics Segment
16. Dormant and Discontinued Products
17. Non-Alcoholic Steatohepatitis Unmet Needs
18. Non-Alcoholic Steatohepatitis Future Perspectives
19. Non-Alcoholic Steatohepatitis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @ [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonalcoholic-steatohepatitis-pipeline-insight-2024-clinical-trials-latest-approvals-therapies-companies-sagimet-biosciences-terns-sinew-pharma-madrigal-pharmaceuticals-hepion-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharma here
News-ID: 3525190 • Views: …
More Releases from ABNewswire
Telecom Providers Can Reduce USF Obligations with Accurate Traffic Studies
Image: https://www.abnewswire.com/upload/2025/11/41653f56cdc8d86a2b4b27ad5074124f.jpg
Every telecom provider in the United States understands the weight of Universal Service Fund (USF) contributions. For many, it's a necessary compliance cost that often goes unquestioned, but what if those payments are actually higher than they need to be? The answer lies in one crucial process: conducting a USF Traffic Study.
Why the USF Contribution Matters
The Universal Service Fund supports critical programs that make telecommunications accessible nationwide, from rural…
Custom Canine Unlimited Strengthens Commitment to Advanced K9 Training Focused o …
Gainesville-based Custom Canine Unlimited expands its specialized K9 training programs, reinforcing its leadership in professional canine development. Focused on safety, performance, and real-world application, the company offers advanced police, protection, and veteran service dog training. Through evidence-based methods and operational expertise, Custom Canine Unlimited ensures exceptional reliability and readiness in every dog-handler team.
Gainesville, Georgia - November 05, 2025 - Custom Canine Unlimited continues to expand and refine its specialized K9…
Local Business Triumph: Causey Orthodontics Receives Excellence in Care Award in …
Causey Orthodontics in Gainesville, GA, is a premier provider of advanced, personalized orthodontic care for all ages. Led by a board-certified specialist, the practice offers comprehensive options, from traditional braces to clear aligners, using cutting-edge technology. Their patient-first philosophy ensures comfort, clear communication, and customized plans for efficient, lasting results. Committed to the North Georgia community, they deliver clinical excellence and trusted, confident smiles.
Gainesville, GA - Causey Orthodontics, a leading…
Visworld vs. Pixverse AI: Comprehensive Platform Comparison for Complete Creativ …
Two Powerful AI Platforms Compete for Market Leadership with Distinct Approaches to Video and Image Generation
The AI video generation market, valued at $720 million in 2025 and projected to reach $2.56 billion by 2032, continues to attract innovative platforms offering diverse creative capabilities. Among the leading contenders, Visworld and Pixverse AI represent two distinct philosophies for AI-powered content creation. While Pixverse AI focuses primarily on video generation with stunning visual…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
